StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Piroxicam

HCID 54676228
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
36322-90-4
Standard-SMILES
CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
InChIKey
QYSPLQLAKJAUJT-UHFFFAOYSA-N
Summenformel
C15H13N3O4S
Durchschnittliche Molmasse
331,3 g/mol
Monoisotopische Masse
331,06267708

Überblick

Piroxicam is a monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide with the exocyclic nitrogen of 2-aminopyridine. A non-steroidal anti-inflammatory drug of the oxicam class, it is used to relieve pain and works by preventing the production of endogenous prostaglandins involved in the mediation of pain, stiffness, tenderness and swelling. It has a role as a non-steroidal anti-inflammatory drug, an analgesic, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, an antirheumatic drug and a cyclooxygenase 1 inhibitor. It is a member of pyridines, a monocarboxylic acid amide and a benzothiazine.

Namen und Bezeichner

Bevorzugter Name
Piroxicam
IUPAC
4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1λ6,2-benzothiazine-3-carboxamide
Lokaler Name
Piroxicam
Englischer Name
Piroxicam
Summenformel
C15H13N3O4S
Molmasse
331.35

Namen und Synonyme

piroxicam36322-90-4FeldenePiroxicamumPyroxycamRoxicamPiroftalBAXOLarapamCP-16171CP 16171CHF 1251
Weitere Namen anzeigen
CB1375282PipoxicamPrioxicam4-HYDROXY-2-METHYL-3-(PYRID-2-YL-CARBAMOYL)-2H-1,2-BENZOTHIAZINE 1,1-DIOXIDEErazonPirkamRiacenZunden
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxideDTXSID502117013T4O6VMAMNSC-6660764-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxidCHEBI:8249CP-16,171NSC666076

Datenbank-Bezeichner

CAS
36322-90-4
PubChem CID
54676228
DTXSID
DTXSID5021170
ChEMBL
CHEMBL1518938、CHEMBL527
ChEBI
CHEBI:8249
UNII
13T4O6VMAM
EC Number
252-974-3

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3,1
Polarare Oberfläche (TPSA)
108 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
2
Schwere Atome
23
Formalladung
0
Komplexität
611

Experimentelle und physikochemische Eigenschaften

Chemical ClassesOther Uses -> Pharmaceuticals
Drugs · 3 Einträge

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Analgesics and anti-inflammatories

LogP · 2 Einträge

3

1.86

Solubility · 2 Einträge

1.43e-01 g/L

>49.7 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 4 Einträge

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 2 Einträge

198-200 °C

198 - 200 °C

Physical Description · 2 Einträge

Solid; [Merck Index]

Solid

Dissociation Constants

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (99%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P264, P270, P280, P301+P316, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 205 reports by companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationPiroxicam: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide: Environment tier I assessment
Hazards Summary · 1 Eintrag

Can cause photo-allergic contact dermatitis; It can also induce systemic photo-sensitivity in patients sensitized to thiomersal. [Kanerva, p. 1827] Piroxicam may induce photosensitivity in patients taking it systemically (photodrug reaction). [Marks, p. 201-3]

Hazard Classes and CategoriesAcute Tox. 3 (99%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Elevated serum aminotransferase levels have been reported in 3% to 18% of patients taking piroxicam, but symptomatic liver disease with jaundice is rare (estimated at 1 to 5 cases per 100,000 prescriptions). The latency to onset of symptoms of clinically apparent liver injury due to piroxicam is variable from a few days to several months, but is generally within the first 1 to 6 weeks of treatment. The pattern of injury is predominantly cholestatic, although cases presenting with mixed or hepatocellular patterns have been reported (Case 1). Eosinophilia, rash and fever can occur, but are not always present and are usually not prominent. Autoantibodies are rarely found. The injury is usually self-limited and recovery occurs within 1 to 2 months. Rare cases of acute liver failure have been reported.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 6 Einträge

M01AC01

M - Musculo-skeletal system

S - Sensory organs

M - Musculo-skeletal system

QM - Musculo-skeletal system

QM - Musculo-skeletal system

Pharmacodynamics · 1 Eintrag

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.

Mechanism of Action · 1 Eintrag

The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.

Biological Half-Life30 to 86 hours
Metabolism/Metabolites · 2 Einträge

Renal

Piroxicam has known human metabolites that include 5'-Hydroxypiroxicam.

FDA Pharmacological Classification · 6 Einträge

13T4O6VMAM

PIROXICAM

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Piroxicam is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of piroxicam is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Zugehörige Reaktionen

41
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 37064
HRID 37064als Edukt
Reaktionsgleichung von HRID 98424
HRID 98424als Edukt
Reaktionsgleichung von HRID 293014
HRID 293014als Edukt
Reaktionsgleichung von HRID 297866
HRID 297866als Produkt
Reaktionsgleichung von HRID 354636
HRID 354636als Produkt
Reaktionsgleichung von HRID 354641
HRID 354641als Produkt
Reaktionsgleichung von HRID 485477
HRID 485477als Produkt
Reaktionsgleichung von HRID 595607
HRID 595607als Edukt
ZurückSeite 1 von 6

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
6.3
Collision Cross Section · 4 Einträge

172.96 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

170.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

170.9 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

170.9 Ų [M+H]+ [CCS Type: TW]

Physikochemische Eigenschaften

Schmelzpunkt
198 · 198-200°C
Dichte
1.3664 · 1.3664 (rough estimate)
Brechungsindex
1.632 · 1.6320 (estimate)
storage temp.
2 · 2-8°C
Löslichkeit
Practically insoluble in water, soluble in methylene chloride, slightly soluble in anhydrous ethanol. It shows polymorphism (5.9).
Aggregatzustand
Solid
pka
6.3 · 6.3 (2:1 dioxane-water)
Farbe
White to Light yellow
Biologische Quelle
synthetic (organic)
Wasserlöslichkeit
Soluble in water, ethanol, chloroform, ethyl acetate.
Merck
14 · 14,7506
BCS Class
2 · 2
Major Application
pharmaceutical (small molecule)
InChI
1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
InChIKey
QYSPLQLAKJAUJT-UHFFFAOYSA-N
SMILES
CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O
CAS Datenbank
36322 · 36322-90-4(CAS DataBase Reference)
NIST chemische Informationen
Piroxicam(36322-90-4)
EPA chemische Informationen
2 H-1,2-Benzothiazine-3-carboxamide, · 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide (36322-90-4)
Adverse EffectsDermatotoxin - PACD (photoallergic contact dermatitis).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Piroxicam

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Piroxicam

0.5

2.0

For the relief of rheumatoid arthritis and osteoarthritis, the recommended dose is 20 mg given orally once per day. If desired, the daily dose may be divided.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 20 mg/day, Lowest Therapeutic Dose (LTD): 0.3 mg/kg-day, and Screening Dose: 0.00008 mg/kg-day.

9-Feb-10

Sicherheitsdaten

wgk
3
ridadr
UN 2811
hs_code
2934999090
RTECS-Nr.
DL0705000
risk_code
22-25
Toxizität
LD50 orally in mice: 360 mg/kg (Wiseman)
hazard_code
Xn,F,T
safety_code
26-36
hazard_class
6.1(b)
packing_group
III
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 3 OralSTOT RE 2 Oral

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 3 Einträge

Well absorbed following oral administration.

Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.

0.14 L/kg

Cellular LocationsCytoplasm
Metabolite PathwaysPiroxicam Action Pathway

Verwendung und Herstellung

Uses · 2 Einträge

Used as anti-inflammatory medication; [Merck Index]

Use (kg; approx.) in Germany (2009): >250

Use ClassificationPharmaceuticals
Anwendungen · 2 Einträge

BeschreibungPiroxieam is a non-steroidal anti-inflammatory drug, of the oxieam class. A contact and photocontact sensitizer, which induced contact dermatitis in a physieal therapist. Piroxieam generally cross reacts with thiosalicylic acid and also with thiomersal. Cross sensitivity is not observed to tenoxicam.

VerwendenPiroxicam is used in inflammatory and degenerative diseases of the musculoskeletal system that are accompanied by painful symptoms. It is used for rheumatic heart disease, nonspecific infectious polyarthritis, gouty arthritis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, arthrosis, back pain, neuralgia, myalgia, and other diseases associated with inflammation.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Ethanol1,2-Benzisothiazol-3(2H)-on-1,1-dioxid, Natriumsalz2-PyridylaminEthyl-chloracetatBenzthiazidMethyljodidNatriumhydroxidHydrogenchloridNatriummethanolatDesmethyl Piroxicam (Piroxicam Impurity B)2-Chloro-N-pyridin-2-yl-acetamide4-Hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid isopropyl ester 1,1-dioxide2-Methyl-1,2-benzisothiazol-3(2H)-on1,1-dioxid

Nachgelagerte Produkte

2-Methyl-4-(1-methylethoxy)-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

Ergänzende Hinweise

DefinitionChEBI: A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide with the exocyclic nitrogen of 2-aminopyridine.